Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +27.42%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.52%
#5 Zilliqa Zilliqa +15.74%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Pharos Pharos +14.68%
#9 Taiko Taiko +14.38%
#10 Cap Cap +13.75%
Coin of the day
Orochi Network Orochi Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rang in aandelen #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Aandeelprijs
$50.93
Marktkapitalisatie
$226.32B
Verandering (1 dag)
2.54%
Verandering (1 jaar)
-26.19%
Land
DK
Handel Novo Nordisk A/S (NVO)

Categorie

Healthcare
Winst voor Novo Nordisk A/S (NVO)
Winst in Mar 2026 TTM: $24.72B
Volgens de meest recente financiële verslagen van Novo Nordisk A/S bedraagt de huidige winst van het bedrijf $24.72B. In 2024 behaalde het bedrijf een winst van $17.75B, een stijging ten opzichte van de winst van 2023, die $15.50B bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Novo Nordisk A/S van 2000 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -79.10%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -79.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -91.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -94.01%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
$586.40M -97.63%
US